Stereotaxis (STXS)

Executive Summary

Stereotaxis is a pioneer in endovascular robotics, specializing in robotic magnetic navigation systems for the treatment of cardiac arrhythmias. Its flagship platform, the Stereotaxis Niobe® system, enables physicians to perform complex electrophysiology (EP) procedures with unparalleled precision, reducing procedure times and radiation exposure. In recent years, the company has focused on expanding its installed base and advancing its technology, including the development of the next-generation Genesis RMN™ system, which promises improved workflow and integration with advanced mapping systems. Stereotaxis has also forged strategic partnerships with leading medical institutions to drive adoption and clinical research. Despite a competitive landscape dominated by manual catheters and emerging robotic systems, Stereotaxis maintains a strong intellectual property portfolio and a differentiated approach based on magnetic navigation. The company's financial performance has shown steady revenue growth, driven by recurring service contracts and capital equipment sales, although profitability remains elusive due to ongoing R&D investments. With the global electrophysiology market projected to grow at a CAGR of over 10%, Stereotaxis is well-positioned to capitalize on rising demand for minimally invasive arrhythmia treatments. Its ability to secure FDA clearances and expand into new geographies will be critical for long-term success.

Upcoming Catalysts (preview)

• Q4 2026FDA approval of Genesis RMN system75% success
• Q3 2026Major hospital network partnership for Niobe system60% success
• Q3 2026Q2 2026 earnings beat with positive guidance55% success